Development of medical termination of pregnancy: a review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28856795.
- Also identified by DOI 10.1111/1471-0528.14905.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy (MTOP). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1-2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP. This article will review the events and challenges leading to the development of the current evidence-based and yet off-label regimen for first-trimester MTOP. This article reviews the events and challenges in the development of medical termination of pregnancy.
Medical subject headings
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents, Nonsteroidal/administration & dosage
- Abortion, Induced
- Abortion, Induced/methods
- Drug Therapy, Combination
- Female
- Humans
- Mifepristone
- Mifepristone/administration & dosage
- Misoprostol
- Misoprostol/administration & dosage
- Pregnancy
- Pregnancy Trimester, First
- Prostaglandins
- Prostaglandins/administration & dosage
- Treatment Outcome